Orgenesis (NASDAQ:ORGS) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET

Company Participants

David Waldman - Investor Relations

Vered Caplan - Chief Executive Officer

Neil Reithinger - Chief Financial Officer

Conference Call Participants

Bruce Jackson - Benchmark Company

Operator

Good morning, ladies and gentlemen and welcome to the Orgenesis Third Quarter 2022 Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Mr. David Waldman, Investor Relations. David, the floor is yours.

David Waldman

Thank you and good morning, everyone and welcome to Orgenesis’ third quarter 2022 business update conference call. On the call with us this morning are Vered Caplan, Chief Executive Officer and Neil Reithinger, Chief Financial Officer. If you have any questions after the call, would like any additional information about the company, please contact Crescendo Communications at 212-671-1020.

This conference call contains forward-looking statements, which are made pursuant to the Safe Harbor provisions of Section 27A of the Securities Act of 1933 as amended in Section 21E of the Securities and Exchange Act of 1934 as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this conference call. We caution listeners that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict.

Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to the risks and uncertainties discussed under the heading Risk Factors in Item 1A of our annual report on Form 10-K for the fiscal year ended December 31, 2021 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Now, I’d like to turn the call over to Orgenesis CEO, Ms. Vered Caplan. Please go ahead, Vered.

Vered Caplan

Thank you, David and thanks to everyone for joining us on our call today. We’ve made significant progress in advancing the rollout of our point-of-care platform, and we are very pleased to report another quarter of solid revenues, $8 million and all progressing in our expansion in the U.S. We have invested much effort in terms of our capital raising activities in order to protect shareholders and preserve our capital structure.